Vivos Inc Expands Global Reach with New Corporate Entity in India
Vivos Inc. Expands Global Presence
Vivos Inc. recently announced a significant development that highlights their commitment to international business expansion. The company's board has authorized the establishment of a wholly owned subsidiary in India, a strategic move aimed at enhancing their global operations.
Formation of Vivos Scientific India LLP
The new subsidiary will be named Vivos Scientific India LLP. This naming process is a crucial step in the overall plan, which the company is currently navigating through the necessary approvals from the Indian government. This decision reflects Vivos Inc.'s dedication to establishing a robust footprint in one of the world's most dynamic markets.
Enhancing Manufacturing and Development
The establishment of a corporate entity in India is aimed not only at creating a manufacturing hub for their innovative products, RadioGel and IsoPet but also at enhancing their capabilities in developmental animal testing. This strategic initiative underscores Vivos Inc.'s long-term vision of expanding their international manufacturing capabilities.
First International Manufacturing Center
Vivos Inc. recognizes the importance of India in their global expansion strategy. The company has already embarked on initiating first-in-human trials in the region, which were previously announced. This pivotal step is crucial for the company as they pursue additional approvals for expanded human trials from the Drug Controller General of India (DCGI).
Collaboration with Regulatory Bodies
As part of their commitment to compliance and safety, Vivos Inc. is preparing to submit formal protocols for the next phases of human trials. These protocols include unique features such as comprehensive post-treatment PET scans that are designed to validate the safety profile of their flagship product, RadioGel. This proactive approach is aimed at aligning their processes with those of the FDA, ensuring that all standards are met with the utmost diligence.
Looking Toward the Future
Vivos Inc. is setting the stage for groundbreaking advancements in both animal and human health treatments. The upcoming trials and establishment of the Indian subsidiary highlight the company’s innovative spirit and dedication to improving health outcomes. Michael K. Korenko, Sc.D., the CEO of Vivos Inc., emphasizes that these efforts are part of a broader commitment to enhance healthcare solutions globally.
Interested parties can reach out to Michael K. Korenko via email to discuss further about Vivos Inc.'s trajectory and innovative products. The company's official website is a resource for more information on their products, RadioGel and IsoPet, aimed at revolutionizing treatment methodologies.
Frequently Asked Questions
What is Vivos Inc.'s primary intention with the new subsidiary?
Vivos Inc. aims to establish a manufacturing center in India and enhance their animal testing and treatment capabilities.
What products will the new subsidiary focus on?
The subsidiary will concentrate on Vivos' innovative treatments, including RadioGel and IsoPet.
When were the first human trials announced in India?
The first human trials were initiated prior to the announcement of the new subsidiary.
How does this move benefit Vivos Inc. in terms of regulatory approvals?
By establishing operations in India, Vivos Inc. aims to align their processes with international standards, facilitating smoother regulatory approvals.
Who can be contacted for more information about Vivos Inc.?
Michael K. Korenko, Sc.D., the CEO, is available for inquiries through email.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
